THE US Food and Drug Administration has issued a warning about a serious genital infection that has occurred in patients with diabetes who are taking sodium-glucose cotransporter-2 (SGLT2) inhibitors.
AstraZeneca told 6minutes it could not establish a causal relationship between their dapagliflozin and Fournier's gangrene while BI and Eli Lilly said they remain "confident in the positive benefit-risk profile of our empagliflozin, and empagliflozin-containing products" - fda.gov.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Sep 18
